Response to Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61

por Wysham, Carol H., Kirkman, M. Sue
Publicado 2011

Practical Considerations for Initiating and Utilizing Flash Continuous Glucose Monitoring in Clinical Practice

por Wysham, Carol H, Kruger, Davida F
Publicado 2021

Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like...

por Wysham, Carol H., Campos, Carlos, Kruger, Davida
Publicado 2018

Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals

por LaRue, Susan, Springer, Jane, Noderer, Michael, Meehan, James, Wysham, Carol H.
Publicado 2018

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes

por Wysham, Carol H., Rosenstock, Julio, Vetter, Marion L., Dong, Fang, Öhman, Peter, Iqbal, Nayyar
Publicado 2017

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week...

por Wysham, Carol H, Rosenstock, Julio, Vetter, Marion L, Wang, Hui, Hardy, Elise, Iqbal, Nayyar
Publicado 2020

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial

por Chaykin, Louis, Bhargava, Anuj, de la Rosa, Raymond, Wysham, Carol H., Nørgård Troelsen, Lone, Østoft, Signe H., Philis-Tsimikas, Athena
Publicado 2019

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

por Wysham, Carol H., Lefebvre, Patrick, Pilon, Dominic, Ingham, Mike, Lafeuille, Marie-Hélène, Emond, Bruno, Kamstra, Rhiannon, Chow, Wing, Pfeifer, Michael, Duh, Mei Sheng
Publicado 2017

Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice‐daily basal insulin to once‐daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (ED...

por Roussel, Ronan, d'Emden, Michael C., Fisher, Miles, Ampudia‐Blasco, F. Javier, Stella, Peter, Bizet, Florence, Cali, Anna M. G., Wysham, Carol H.
Publicado 2017

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data

por Young, James B., Gauthier-Loiselle, Marjolaine, Bailey, Robert A., Manceur, Ameur M., Lefebvre, Patrick, Greenberg, Morris, Lafeuille, Marie-Hélène, Duh, Mei Sheng, Bookhart, Brahim, Wysham, Carol H.
Publicado 2018

Day‐to‐day fasting self‐monitored blood glucose variability is associated with risk of hypoglycaemia in insulin‐treated patients with type 1 and type 2 diabetes: A post hoc analysi...

por DeVries, J. Hans, Bailey, Timothy S., Bhargava, Anuj, Gerety, Gregg, Gumprecht, Janusz, Heller, Simon, Lane, Wendy, Wysham, Carol H., Zinman, Bernard, Bak, Britta A., Hachmann‐Nielsen, Elise, Philis‐Tsimikas, Athena
Publicado 2018

Diabetes Performance Measures: Current Status and Future Directions

por O'Connor, Patrick J., Bodkin, Noni L., Fradkin, Judith, Glasgow, Russell E., Greenfield, Sheldon, Gregg, Edward, Kerr, Eve A., Pawlson, L. Gregory, Selby, Joseph V., Sutherland, John E., Taylor, Michael L., Wysham, Carol H.
Publicado 2011